The bank sees 2012 EPS of $1.33, up from $1.26 per share, and 2013 EPS of $1.69, up from $1.65 per share.
Alexion Pharmaceuticals is currently above its 50-day moving average (MA) of $47.96 and above its 200-day of $43.91.
Morgan Stanley raised its price target for Alexion Pharmaceuticals (NASDAQ:ALXN) to $61 from $56 and maintained its overweight rating on the stock.
